Focus on drug delivery technology platforms for improving the safety and efficacy of currently available drugs, particularly oncology drugs.
Xinyi Dist, Taipei 110, Taiwan
Drug development company. Pipeline of four drugs in preclinical stage: LBS-008 for Dry AMD; LBS-007 for Acute Leukemia; and LBS-002 and LBS-003 for oncology applications.
LBS-002 was acquired from the University of Sydney in March 2017, and has shown an ability to cross the blood-brain barrier with the potential for treating both primary and metastatic brain cancers.
Drug development, particularly for cancer, vaccines, IV diagnostics, generic drugs. Has three subsidiaries: Medigen Vaccine Biologics Corporation, TBG Diagnostics Limited, and Winston Medical & Biotech Group.
Mesenchymal stem cells (MSCs) research and drug development, as well as diagnostic techniques and drug screening platform through partnerships.
Biologics Contract Manufacturing Organization (CMO) and developer of biosimilars. Products include: TuNEX®(etanercept), LusiNEX (tocilizumab), AiNEX (bevacizumab), GranNEX (G-CSF), Omalizumab, Adalimumab, Trastuzumab.
Taipei, 11503, Taiwan
R&D expertise in developing novel cancer and infectious disease therapies. Lead product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The company is also the license holder for DIFICID in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.